Novartis Itvisma Gains CHMP Boost for SMA Therapy
Basel, Switzerland | April 24, 2026 In a major breakthrough for rare disease treatment, Novartis has received a positive...
Neurology
Advertisement
Johnson & Johnson IMAAVY Delivers 2-Year gMG Control
HORSHAM, Pa., April 22, 2026 Johnson & Johnson has reported compelling long-term Phase 3 data demonstrating that IMAAVY® (nipocalimab-aahu)...
Roche ENSPRYNG Shows MOGAD Clinical Benefit Data
BASEL, Switzerland, April 2026 Roche reported new clinical findings demonstrating the effectiveness of ENSPRYNG® (satralizumab) in reducing relapse risk...
Monopar Reports Phase 3 ALXN1840 Data at AAN 2026
WILMETTE, Ill., April 19, 2026 Monopar Therapeutics announced new Phase 3 clinical data demonstrating greater neurologic benefit of ALXN1840...
Mapi Pharma GA Depot Shows Strong MS Progression Control
NESS ZIONA, Israel, April 16, 2026 Mapi Pharma Ltd. has announced new clinical findings demonstrating that its Glatiramer Acetate...
Advertisements
Neurelis Shows Strong Seizure Control Data for VALTOCO at AAN
SAN DIEGO, Calif., April 16, 2026 Neurelis, Inc. has announced new clinical and real-world analyses demonstrating the effectiveness of...
MemorialCare Joins FASTEST Trial for Stroke Therapy
LONG BEACH, Calif., April 2026 MemorialCare Long Beach Medical Center has joined a nationwide Phase 3 clinical research effort...
Rapport Presents Phase 2 Data for Epilepsy Drug RAP-219
BOSTON & SAN DIEGO, USA — April 1, 2026 Rapport Therapeutics, Inc. announced that it will present new Phase...
Ionis Zilganersen NDA Gets FDA Priority Review
CARLSBAD, California, March 23, 2026 Ionis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted...
Vasomune AV-001 Trial Begins for Brain Protection
TORONTO, CANADA | March 24, 2026 A significant milestone has been reached in clinical-stage biopharmaceutical research as the first...
Advertisement
